Table 1 Patients’ clinical characteristics
From: Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
Patient # | Age (years) | PSA (ng/ml) | Prior therapy | miTNM stage |
|---|---|---|---|---|
#01 | 58 | 320 | Bicalutamide enzalutamide, docetaxel, cabazitaxel | T3 N1 M1c (liver) |
#02 | 49 | 2914 | LHRH, bicalutamide enzalutamide, docetaxel, 2 × 177Lu-PSMA 617 | Tx Nx M1a M1b (bone, lymph nodes) |
#03 | 60 | 100 | Docetaxel, samarium, enzalutamide, 4 × 177Lu-PSMA 617 | T4 N1 M1a M1b (bone, lymph nodes) |